Jove
Visualize
Contact Us

Related Concept Videos

Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

49
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
49
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

33
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
33
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

47
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
47
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

32
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
32
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

53
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
53
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

28
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
28

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adaptive Cavity-Enabled Crystalline Chirality in Nanocarbon Cages.

Angewandte Chemie (International ed. in English)·2026
Same author

Facile Preparation of a Poly[2]Catenane Network Using Self-Assembled [2]Catenane Unit.

Angewandte Chemie (International ed. in English)·2026
Same author

Fused Metallo-Carbaporphyrin-Embedded Graphene Nanoribbon Segments.

Journal of the American Chemical Society·2026
Same author

Recognition-Based Chiral Amplification through Adaptive Locking.

Journal of the American Chemical Society·2026
Same author

Nanobody-Conjugated Theranostic Prodrug Targeting α<sub>v</sub>β<sub>3</sub> Integrin Enables Precision Cancer Therapy With Real-Time Imaging.

Advanced healthcare materials·2026
Same author

A next-generation multimetal complex induces immunogenic cell death with distinct transcriptomic signatures.

Chemical communications (Cambridge, England)·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 21, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.6K

A pH responsive complexation-based drug delivery system for oxaliplatin.

Bin Li1,2, Zhao Meng2, Qianqian Li1

  • 1Department of Chemistry , Center for Supramolecular Chemistry and Catalysis , Shanghai University , Shanghai 200444 , P. R. China . Email: sessler@mail.utexas.edu ;

Chemical Science
|October 4, 2017
PubMed
Summary
This summary is machine-generated.

A novel drug delivery system encapsulates oxaliplatin (OX) using a pH-responsive receptor, improving its stability and tumor targeting. This approach enhances OX

More Related Videos

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.1K
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

9.9K

Related Experiment Videos

Last Updated: Feb 21, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.6K
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.1K
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

9.9K

Area of Science:

  • Supramolecular Chemistry
  • Materials Science
  • Nanotechnology

Background:

  • Oxaliplatin (OX) faces challenges like rapid degradation, poor tumor selectivity, and low bioavailability.
  • A pH-responsive drug delivery system (DDS) is needed to enhance OX efficacy.

Purpose of the Study:

  • To design a responsive DDS for oxaliplatin (OX) using carboxylatopillar[6]arene (CP6A).
  • To overcome OX's limitations by improving its stability, tumor selectivity, and bioavailability.

Main Methods:

  • Host-guest encapsulation of OX by CP6A.
  • Assessment of binding affinities at biologically relevant pH (7.4 and 5.4).
  • Evaluation of in vitro cytotoxicity in cancer cell lines (HepG-2, MCF-7, A549).
  • Measurement of OX stability in plasma.
  • In vivo studies using sarcoma 180 (S180) tumor xenografts in mice.

Main Results:

  • CP6A exhibits pH-sensitive binding affinities for OX, with significantly higher affinity at pH 7.4 compared to pH 5.4.
  • OX encapsulation by CP6A did not alter its in vitro cytotoxicity.
  • CP6A complexation increased OX stability in plasma by 2.8-fold over 24 hours.
  • The CP6A⊃OX complex significantly enhanced OX's ability to inhibit tumor regrowth in vivo.

Conclusions:

  • The CP6A⊃OX host-guest complex offers a promising strategy for oxaliplatin (OX) drug delivery.
  • Enhanced stability and pH-responsive release contribute to improved in vivo anticancer activity.
  • The system effectively delivers OX to the acidic tumor environment, overcoming limitations of conventional OX therapy.